This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Familial medullary thyroid carcinoma [3 genes]
Around 25% of medullary thyroid carcinoma (MTC) cases are hereditary, associated with alterations in the RET gene in the germinal line. Depending on the type of mutation, these variants can cause multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma (FMTC). FMTC has a dominant autosomal inheritance pattern and represents 15% of hereditary MTC syndromes.
Request study
Informed consent
Steps to follow
Ask for information
Steps to follow
How to order
1. Download & fill out
Please cover as many fields as possible in both documents
2. Sample collection
Three sample types: saliva, peripheral blood or genomic DNA
3. Pack the sample
Please pack the sample in a way to prevent leakage
4. Send the sample & the request
Please schedule the delivery for Mon–Thur: 8am – 5pm
5. Result: the report
Via: Client Site HIC / Client Site Imegen / Certified email
Solicita información de
Familial medullary thyroid carcinoma
Turnaround time (TAT): 4 weeks
Ref. S-201804750
Familial medullary thyroid carcinoma: View panel
- MEN1
- RET
- CDKN1B
Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.